Current understanding of the pharmacogenomics of metformin

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 6, 2009, Pages 595-598

  Zolk, O ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; CIMETIDINE; METFORMIN; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN KINASE; TETRYLAMMONIUM; UNCLASSIFIED DRUG;

ALLELE; BILIARY EXCRETION; BLOOD LEVEL; CELL CULTURE; CREATININE CLEARANCE; DNA POLYMORPHISM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MARKETING; DRUG RESPONSE; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GLYCEMIC CONTROL; HUMAN; IN VITRO STUDY; KIDNEY; KIDNEY CLEARANCE; KIDNEY EPITHELIUM; KIDNEY TUBULE EXCRETION; LACTIC ACIDOSIS; LIVER; MEMBRANE VESICLE; MOLECULAR CLONING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE DISTRIBUTION; TREATMENT FAILURE; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; METFORMIN; OCTAMER TRANSCRIPTION FACTOR-1; ORGANIC CATION TRANSPORT PROTEINS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 70450149001     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.144     Document Type: Review

References (13)

1. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83, 273-280 (2008).
2. Song, I.S. et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther. 84, 559-562 (2008).
3. Wang, Z.J., Yin, O.Q., Tomlinson, B. & Chow, M.S. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics 18, 637-645 (2008).
4. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431 (2007).
5. Tzvetkov, M.V. et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86, 299-306 (2009).
6. Jonker, J.W. et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol. Cell. Biol. 21, 5471-5477 (2001).
7. Zhou, K. et al. Reduced function SLC22A1 polymorphisms encoding Organic Cation Transporter 1 (OCT1) and glycaemic response to metformin: a Go-DARTS study. Diabetes 58, 1434-1439 (2009).
8. Shikata, E. et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J. Hum. Genet. 52, 117-122 (2007).
9. Becker, M.L., Visser, L.E., van Schaik, R.H., Hofman, A., Uitterlinden, A.G. & Stricker, B.H. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58, 745-749 (2009).
10. Sirtori, C.R. et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin. Pharmacol. Ther. 24, 683-693 (1978).
11. Tucker, G.T., Casey, C., Phillips, P.J, Connor, H., Ward, J.D. & Woods, H.F. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. 12, 235-246 (1981).
12. Tsuda, M., Terada, T., Mizuno, T., Katsura, T., Shimakura, J. & Inui, K. Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol. 75, 1280-1286 (2009).
13. Chen, Y. et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin, Pharmacogenet. Genomics 19, 497-504 (2009).